A phase 2 clinical trial reports that sitagliptin, an existing diabetes drug, can overcome gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition. The trial record is listed on PubMed and ClinicalTrials.gov, as of 3 November 2026.^[1] The single-centre SITGEM-CARE trial enrolled 22 patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Median patient age was 65.0 years. 68.2% of participants had stage IV disease. Researchers used AI-guided structure-based drug repurposing to select sitagliptin as a candidate ribonucleotide reductase inhibitor. Sitagliptin is an approved DPP-4 inhibitor for diabetes. This work appears in Signal Transduction and Targeted Therapy. The PubMed entry carries identifier 42971953.